Diabetic Nephropathy Trial Results Selected For

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Diabetic Nephropathy Trial Results Selected For Late-Breaking Presentation At American Diabetes Association Annual Meeting

NEW YORK and MELBOURNE, Australia, May 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that Phase 2 trial results of its lead product candidate for the treatment of diabetic nephropathy have been selected for presentation at the late-breaking scientific sessions of the 75th American Diabetes Association (ADA) Scientific Sessions being held from June 5-9 in Boston, MA. The annual meeting is the largest diabetes meeting in the world, bringing together approximately 14,000 participants, including clinicians and researchers from 124 countries.

As many as 40-50% of people with type 2 diabetes develop progressive decline in renal function due to nephropathy (or kidney disease), despite use of existing therapies. These patients have a high rate of progression to dialysis and death due to cardiovascular events. Abnormal chronic inflammation and microvascular dysfunction which persist in the diabetic kidney over many years are thought to be important causal factors in the development of progressive diabetic nephropathy.

Mesoblast is developing its allogeneic mesenchymal precursor cell (MPC) product candidate, MPC-300-IV, for intravenous delivery in the treatment of specific conditions caused by excessive inflammation and endothelial dysfunction, including biologic-refractory rheumatoid arthritis and diabetic nephropathy. By down-regulating pro-inflammatory cytokines produced by monocytes and T cells, MPCs may counteract the destructive inflammatory processes and vascular dysfunction implicated in these diseases.

To establish an MPC dose range that is safe and effective for use in diabetic patients, Mesoblast initially performed a randomized, placebo-controlled, dose-escalating Phase 2 trial in patients with type 2 diabetes, insulin resistance and poor glycemic control, but without kidney disease. In that trial, a single infusion of allogeneic MPCs resulted in a dose-dependent improvement in hemoglobin A1c levels (HbA1c), the recommended primary endpoint by the FDA for glycemic control in diabetic patients. The greatest decrease relative to placebo was seen at eight weeks following a single dose of 2 million MPCs/kg or a total dose of at least 150 million MPCs (p is less than 0.05).

Using this dose-range as a guide, Mesoblast conducted a double-blind, randomized, placebo-controlled, dose-escalation Phase 2 trial in 30 patients with type 2 diabetes and moderate to severe renal impairment, stage 3b-4 chronic kidney disease ( www.clinicaltrials.gov/ct2/show/NCT01843387 ). The objectives of the trial were to evaluate safety and tolerability of a single infusion of 150 or 300 million MPCs in patients with diabetic nephropathy, and to explore potential efficacy signals in terms of renal function and biomarkers of inflammation at 12 weeks, with ongoing follow-up for an additional 48 week period. These results will be presented by the trial's principal investigator at the upcoming ADA meeting.

Diabetic Nephropathy

Diabetic nephropathy is the single leading cause of end-stage kidney disease, accounting for nearly half of all end-stage kidney disease cases in the United States. There were an estimated 1.96 million cases of severe diabetic nephropathy in 2013. The current standard of care (renin-angiotensin system inhibition with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers) only slows the rate of progression to kidney failure by 16-25%, leaving a large residual risk for end-stage kidney disease. For patients with end-stage kidney disease, the only treatment option is renal replacement (dialysis or kidney transplantation) which incurs high medical costs and substantial disruptions to a normal lifestyle. Due to a severe shortage of kidneys, in 2012 approximately 92,000 persons in the United States died while on the transplant list. For those on dialysis, the mortality rate is high with an approximately 40% fatality rate within two years.

Mesoblast Limited

Mesoblast Limited (ASX: MSB; USOTC: MBLTY) is a global leader in regenerative medicine. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic or 'off-the-shelf' cell product candidates target significantly advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic/inflammatory disorders and oncology/hematology conditions. The lead therapeutic product candidates under investigation include MPC-150-IM for chronic congestive heart failure; MPC-06-ID for chronic discogenic low back pain, MSC-100-IV for acute graft versus host disease, and MPC-300-IV for biologic refractory rheumatoid arthritis, and diabetic nephropathy.

For further information, please contact: Julie Meldrum Global Head of Corporate Communications Mesoblast Limited T: +61 (0) 3 9639 6036 E: julie.meldrum@mesoblast.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 64

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Pepsi Faces Georgia Labor Pressure Ahead of Strike

Updated Category News Views 73

A Pre-Dawn Labor Test Is Brewing in Georgia At 2:30 in the morning, nobody gathers outside a distribution center for the scenery. More than 100 Pepsi-Cola drivers from Atlanta and Lithonia are slated to meet Tuesday, November 24, at the Pepsi Distribution Center in Lithonia, Georgia, with Teamsters General President Sean M. O'Brien joining them. That hour matters. It puts...

Continue Reading
Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 71

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 52

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 56

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 47

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading

Top 5 Most Recently Viewed Articles

Happy Day Brands and Sysco's Powerful Partnership for Change

Updated Category News Views 213

Happy Day Brands and Sysco Unite to Fight Hunger Happy Day Brands is stepping into the spotlight with an exciting partnership alongside Sysco that aims to nourish communities during a time when support is crucial. This collaboration is set to engage multiple states in a significant act of community service. Together, they will package over one million servings of...

Continue Reading
Upcoming Market Trends: The Influence of Trade Tensions

Updated Category News Views 245

Market Dynamics Shaped by Trade Tensions As we enter a new trading week, the economic landscape is painted with the resurgence of trade tensions. The discussions around tariffs, notably involving major economies, signal a return to aggressive trade policies that could influence market behavior. Understanding the Impact of Tariffs The reintroduction of tariffs has stirred...

Continue Reading
Carma HoldCo Invests in Mr. Charlie's for Plant-Based Growth

Updated Category News Views 150

Carma HoldCo Expands into Plant-Based Fast Food Market Carma HoldCo, renowned for its innovative brand portfolio, is making a significant leap into the plant-based quick-service restaurant (QSR) sector through a strategic investment in Mr. Charlie's Told Me So (TMS). This exciting partnership underlines the growing trend of health-conscious dining, particularly as...

Continue Reading
Advent Technologies to Showcase Innovative Maritime Solutions

Updated Category News Views 179

Advent Technologies Takes Center Stage at IEA Conference Advent Technologies Holdings, Inc. (NASDAQ: ADN) has announced that Dr. Emory De Castro, the Chief Technology Officer, will participate in the upcoming International Energy Agency (IEA) conference, set to occur in a prominent location soon. This event focuses on fuel cell applications within the maritime industry....

Continue Reading
Growing Demand in Polarized Sunglasses Market

Updated Category News Views 23

Polarized Sunglasses Gaining Traction Get this—polarized sunglasses are catching eyes like a bandwagon with NOS. Consumer365 just threw a nod at EZContacts for their impressive lineup of designer shades that promise to cut the glare while keeping those retinas comfy from the sun's death rays. Understanding the Hype Around Polarized Lenses Look, if you're fed up with...

Continue Reading